

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Wallace, Daniel J.

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Clinical Professor of Medicine

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Southern California	BS	1970	Medicine
University of Southern California	MD	1974	Medicine
Brown University, Providence RI	Internship	1975	Internal Medicine
Cedars-Sinai Medical Center	Residency	1977	Internal Medicine
UCLA School of Medicine	Fellowship	1979	Rheumatology

A. Personal Statement

I have been practicing clinical rheumatology since 1979 with a special interest in systemic lupus erythematosus (SLE). I was fortunate to take over the practice of Dr. Edmund Dubois on his passing in 1985 and developed the largest single practitioner lupus cohort in the United States. Our institution has participated in SLICC, the Lupus Clinical Trial Consortium, and AROSE criteria committee. I have been editor of the last 6 editions of Dubois' Lupus Erythematosus, and the patient handbook "The Lupus Book" has sold over 125,000 copies. Our center has performed over 100 lupus clinical trials, biomarker, genetics, quality of life and SLE metric studies as well as 353 peer reviewed publications and 20 book chapters. I have had first authorship on manuscripts relating to celecoxib, mycophenolate mofetil, leflunomide, riqvent, belimumab and epratuzumab, and six publications (half as lead author) in the New England Journal of Medicine. My efforts have resulted in raising \$10 million for lupus research and establishing an endowed chair in rheumatology at my institution. Our center is excited by the prospect of participating in the mesenchymal stem cell trial. We have the patients, technical expertise, coordinators and facility to do an outstanding job in carrying out this trial.

- Wallace DJ, Hahn BH (2013). *Dubois' Lupus Erythematosus and Related Syndromes, 8th edition*. Philadelphia, PA: Elsevier Saunders.
- Wallace DJ (2012). *The Lupus Book: A Guide for patients and their families*. New York, New York: Oxford University Press.
- Wallace DJ (2014). *Lupus: The Essential Clinician's Guide, 2nd edition*. New York, New York: Oxford University Press.

B. Positions and Honors

1979-1981	Assistant Clinical Professor, USC School of Medicine
1979-present	Attending Physician, Cedars-Sinai Medical Center, Los Angeles CA
1979-present	Consulting Physician, Century City Hospital – (1982-1984, Chief of Rheumatology)
1980-1988	Chief Rheumatology Consultant, City of Hope Medical Center, Duarte CA
1981-1988	Assistant Clinical Professor, UCLA School of Medicine
1981-present	Attending Physician, UCLA Center for the Health Sciences
1988-1995	Associate Clinical Professor, UCLA School of Medicine
1991-1996	Clinical Chief of Rheumatology, Cedars-Sinai Medical Center, Los Angeles CA
1995-present	Clinical Professor, David Geffen School of Medicine at UCLA
1997	Outstanding Service Award, Lupus Foundation of America
2001	"Spirit of Hope" Award, Southern California Scleroderma Foundation
2002	Achievement Award, SLE Foundation
2004	James R. Klinenberg Achievement Award, Arthritis Foundation of Southern California

2008	Founder's Award, Lupus LA, SLE Foundation
2010-present	Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center
2012	Sjogren's Syndrome Foundation, Healthcare Professional Leadership Award

Other experience and professional memberships

1990-1997	United Scleroderma Foundation Board of Directors
1999-2000	Lupus Foundation of America Board of Directors 1992-2000; Chairman 1999-2000
1990-1999	Research & Education Foundation of the Amer. College of Rheumatology Board of Directors
1995-1999	Chairman, Research & Education Foundation of the Amer. College of Rheum Board of Directors
1997-present	Sjogren's Syndrome Foundation, Medical Advisory Board
2005-2010	Lupus Clinical Trials Consortium
2000-present	Lupus Research Institute Board of Directors, 2012-present, Co-Chair Lupus Industry Council
2003-present	Systemic Lupus International Collaborative Clinics member

C. Contribution to Science

1. When my mentor, Edmund L Dubois MD, passed away in 1985, I inherited his lupus patients. Currently, my office manages the care of 1500 patients with SLE, the largest practice of its kind in the United States. I have had the opportunity to author scores of publications on this cohort regarding clinical features, nephritis, cutaneous disease, central nervous manifestations, laboratory testing, imaging, treatments and outcome. This has led to numerous landmark insights including the role of microvascular angina as a cause of lupus chest pain, "watershed region" vasculopathy producing 'lupus fog' without vasculitis, the first paper associating SLE with fibromyalgia, investigations into sex disparities, accelerated atherogenesis, and novel treatments such as hyperbaric oxygen, cyclosporine and quinacrine.
 - a. Wallace D, Podell T, Weiner J, Klinenberg J, Forouzes S, Dubois E, Systemic Lupus Erythematosus—survival patterns: Experience with 609 patients, JAMA 245: 934-938, 1981.
 - b. Wallace DJ, Podell TE, Weiner J, Cox M, Klinenberg J, Forouzes S, Dubois EL, Lupus nephritis: Experience with 230 patients in a private practice from 1950-1980, Am J Med 72: 209-220, 1982.
 - c. McMahan M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH, Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis, Arthritis Rheum. 2006 Aug;54(8):2541-9.
 - d. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, Waxman AD, Weisman MH, Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus, Arthritis Rheum. 2008 Mar 15;59(3):332-7. doi: 10.1002/art.23308.
2. I started one of the first clinical trials center for innovative and targeted therapies for rheumatoid arthritis and lupus. We have been a participant in some of the leading lupus treatment protocols for the last 30 years, and have pioneered improved methodologies, metrics and outcome measures among others.
 - a. Wallace DJ, Goldfinger D, Lower C, Nichols S, Weiner J, Brachman M, Klinenberg J, A double-blind controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis, N Eng J Med 306: 1406-1410, 1982.
 - b. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med 2005; 353: 2219-2228.
 - c. Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, Mc Cune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW, A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus, Arthritis Rheum 2009; 61: 1168-1178.
 - d. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kalgallen B, Bongardt S, Barry A, Kelley L, Gordon L, Efficacy and safety of epratuzumab in aptients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled multicentre study, Ann Rheum Dis 2014; 73: 183-190.
3. Antimalarial drugs are one of the most important agents in the clinical management of rheumatic diseases. Our group has published guidelines and new basic science insights in this area, which have been cited over 1000 times.

- a. Wallace DJ, The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination, *Seminars Arthritis Rheum* 18:282-297, 1989
 - b. Wallace DJ, Does hydroxychloroquine sulfate prevent clot formation in SLE? *Arthritis Rheum* 30: 1435-1436. 1987.
 - c. Wallace DJ, Metzger AL, Stecher VJ, Tumbull BA, Kern PA, Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids, *Amer J Med* 89:322-326, 1990.
 - d. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR, New insights into mechanisms of therapeutic effects of antimalarial agents in SLE, *Nat Rev Rheumatol* 2012; 8: 522-533.
4. Our group was the first to recognize the importance of IL-6 and vitamin D in SLE, long before anybody else was doing research in this area. They are now thought to be important in the immune regulation of SLE. This is still an active area of investigation for our group.
- a. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR, Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis, *J Immunol* 147:117-123, 1991.
 - b. Wallace DJ, Popa S, Spindler AJ, Eimon A, Gonzalez-Rivera T, Utset TO, Petri M, Lipsky PE, Merrill JT, Strand V, Wajdula J, Christensen J, Li C, Diehl A, Vincent M, Beebe, Sridharan S, Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody in subjects with active generalized systemic lupus erythematosus (SLE), *Arthritis Rheum* 2014; 66: 3531
 - c. Chong PJ, Matzner WL, Wallace DJ, Klinenberg JR, Toyoda M, Jordan SC, 1-25 dihydroxyvitamin-D3 regulation of immunoglobulin production in peripheral blood mononuclear cells in patients with systemic lupus erythematosus, *Journal of Autoimmunity*, 2:861-867, 1989.
 - d. Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Merrill J, Wallace DJ, Ginzler E, Khamashta M, Bruce I, Nived O, Sturfelt G, Steinsson K, Manzi S, Dooley MA, Kalunian K, Petri M, Aranow C, Font J, van Vollenhoven R, Stoll T, Ramsey-Goldman R, 25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: Data from a large international inception cohort *Arthritis Care Res* 2014; Jan 27, doi 10.1002/acr22291 (Epub ahead of print).
5. One of my proudest achievements is the discovery of a new autoantibody that is pure anti-dsDNA and which may have profound implications in SLE and its role with aging. Anti-telomere antibodies represent an unexplored frontier for future lupus research.
- a. Wallace DJ, Salonen E-M, Avaniss-Aghajani E, Morris R, Metzger AL, Pashinian N, Anti-telomere antibodies in systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications, *Lupus* 2000; 9:328-332.
 - b. Honda M, Mengesha E, Albano S, Nichols WS, Wallace DJ, Metzger A, Klinenberg JR, Linker-Israeli M, Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase positive CD8+CD28- T-cells in patients with systemic lupus erythematosus, *Clin Immunology* 2001; 99: 211-221.
 - c. Wallace DJ, Telomere diseases, *New Engl J Med* 2010; 362:1150.

D. Research Support

Ongoing (selected)

Sanofi USA Services, Inc.

Wallace (PI)

2/20/13 – open

A longitudinal observational study of CXCR5, CXCL13 and other biomarkers in patients with lupus and healthy control subjects

5U19 AI219711056363-10

St. Clair (PI)

5/01/13 – open

An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable Quiescent Systemic Lupus Erythematosus (SLE).

The primary objective of this study is to describe the effect of withdrawal from MMF on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

Role: Co-Investigator

France Foundation Wallace (PI) 9/2012 – open
Improving the Recognition, Diagnosis, and Referral Patterns of patients with Systemic Lupus Erythematosus through Enhanced Care Coordination and Practice Efficiencies
This is a QI/PI CME demonstration project for the Cedars-Sinai Medical Group

DOD / Immunomedics, Inc. Wallace (PI) 6/02/14 – open
IMMU-115-4 SLE A Phase 1b Study of Milatuzumab Administered Subcutaneously in Patients with Active Systemic Lupus Erythematosus (SLE).
The primary objective of this study is to demonstrate that subcutaneously administered milatuzumab is safe in patients with SLE, to collect pharmacokinetic, pharmacodynamic, and immunogenicity data in this population, and to obtain preliminary evidence of efficacy for patients with active disease.

R34 A114453 Gilkeson/Kamen (PI) 7/15/14 – 6/30/15
Mesenchymal Stem Cell Therapy for Active Systemic Lupus Erythematosus
The purpose of this Planning Grant is to complete protocol development and set up the administrative and regulatory structures necessary at each of the sites for successful implementation of a Phase II multicenter placebo controlled trial evaluating efficacy and safety of allogeneic MSCs for the treatment of adults with moderate to severely active SLE.
Role:Co- Investigator

5P50 AR060804-03 Sivils (PI) 7/01/13 – 6/30/15
Oklahoma Sjogren's Syndrome Center of Research Translation
The overall specific aim is to establish the Oklahoma Sjogren's Syndrome Center of Research Translation (OSSCORT) with the goal of bridging the gap between the advances in the basic-science understanding of Sjogren's syndrome and clinical research geared to improving better diagnostics, disease predictors, and prognostic tests, as well as to advance therapeutic options.
Role: Co-Investigator

Completed (selected)

N01 AI15416 Bluestone (PI) 01/01/08 – 04/30/14
A Randomized, Double-blind, Controlled, Phase II Multicenter Trial of CTLA4lg (Abatacept) Plus Cyclophosphamide Alone in the Treatment of Lupus Nephritis.
The primary objective of this study is to determine whether induction therapy with abatacept plus cyclophosphamide improves the response rate in patients with lupus nephritis.
Role: Co-Investigator